OncoFAP

OncoFAP is a small molecule radiotracer with ultra high affinity for Fibroblast Activation Protein (FAP). The product is suitable for the non-invasive detection of a variety of metastatic solid tumors, as FAP is overexpressed in more than 90% of epithelial cancers (e.g., malignant breast, colorectal, ovarian, lung, skin, prostate and pancreatic cancers, as well as in some soft tissue and bone sarcomas).

The OncoFAP product consists of a (i) small organic ligand targeting FAP, (ii) an innovative spacer structure and (iii) a DOTAGA chelator. 

OncoFAP displays best-in-class performance both in vitro  and in vivo with the highest reported affinity to the FAP antigen. In preclinical models of cancer, the product has shown a very rapid and selective accumulation in the tumor mass with an exceptionally low kidney uptake.

Thanks to the pan-tumoral potential of the ligand, OncoFAP-68Ga is being developed for the imaging of different tumor entities.

ONGOING CLINICAL TRIALS
  • OPTION 1: OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers.
  • OPTION 2: OncoFAP-68Ga has successfully been administered for the diagnosis of cancer patients with advanced solid malignancies (compassionate use).

ONGOING CLINICAL TRIALS

  • OPTION 1: OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers.
  • OPTION 2: OncoFAP-68Ga has successfully been administered for the diagnosis of cancer patients with advanced solid malignancies (compassionate use).
References
  • Millul et al. (2021) PNAS, online ahead of print